Zhiwei Hu


M. D. Medicine and Stomatology, Jiangxi Medical College, China, 1991
M. S. Tumor Immunology, Jiangxi Medical College, China, 1994
Ph. D. Tumor Immunobiology, Hunan Medical University, China, 1997

Highlight Of Qualifications

  • 20-year experiences in tumor immunology, oncology and cancer immunotherapy and diagnosis using monoclonal antibody, phage display antibody and recombinant factor VII/IgG1 Fc (Icon) immunoconjugates
  • 15-year experiences in molecular biology, adenoviral gene therapy for cancer and 10-year experiences in targeted photodynamic therapy for cancer and macular degeneration
  • Principal Investigator and Research Associate Professor (Research Scientist) of a research laboratory at Yale School of Medicine during 2002-2012
  • Recipient and Principal Investigator of four independent research grants from Komen For the Cure Foundation, Connecticut State Department of Public Health, Breast Cancer Alliance and Swebilius Foundation/Yale Cancer Center
  • 7-year experiences as Scientific Advisor for Iconic Therapeutics, a Yale startup biotech company
  • Co-inventor of 5 US Patents and 4 international patents of neovascular-targeted immunoconjugates (ICON) and their uses (for treatment of cancer, macular degeneration, rheumatoid arthritis, atherosclerosis, etc)
  • Serving as the Editor-in-Chief of Open Journal of Immunology, Co-Editor-in-Chief of the Journal of Analytical & Bioanalytical Techniques, an editorial board member of numerous peer-reviewed journals in immunology and cancer research and as peer reviewer for peer-reviewed journals in immunology, photomedicine and cancer research
  • Served as Co-Principal Investigator on an Investigator IND for Phase I clinical trial of the use of replication-deficient adenoviral vector encoding a novel immunoconjugate (Icon) composed of coagulation active site-mutated factor VII fused to the constant domain of immunoglobulin G (IgG Fc) for immunotherapy of patients with melanoma
  • Extensive experience with primary immune cells of human and rodent origins, in vitro and in vivo preclinical studies on efficacy and safety of translational cancer research
  • Excellent communication skills, both verbal and written, and strong interpersonal skills and presentation skills as well as a robust publication record in peer-reviewed journals
  • Innovative, strong logical and analytical thinking skills and experiences in discovery and development of targeted cancer therapies
  • A team player


Associate Professor of Surgical Oncology
The Ohio State University